Olumiant

Product manufactured by Eli Lilly And Company

Application Nr Approved Date Route Status External Links
NDA207924 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Olumiant ® Is A Janus Kinase (Jak) Inhibitor Indicated For The Treatment Of Adult Patients With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To One Or More Tnf Antagonist Therapies. ( 1.1 ) Limitation Of Use : Not Recommended For Use In Combination With Other Jak Inhibitors, Biologic Dmards, Or With Potent Immunosuppressants Such As Azathioprine And Cyclosporine. ( 1.1 ) 1.1 Rheumatoid Arthritis Olumiant ® (Baricitinib) Is Indicated For The Treatment Of Adult Patients With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To One Or More Tumor Necrosis Factor (Tnf) Antagonist Therapies. Limitation Of Use : Not Recommended For Use In Combination With Other Jak Inhibitors, Biologic Disease-Modifying Antirheumatic Drugs (Dmards), Or With Potent Immunosuppressants Such As Azathioprine And Cyclosporine.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Baricitinib BARICITINIB ZINC73069247

Comments